X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (480) 480
Conference Proceeding (56) 56
Publication (40) 40
Book Review (26) 26
Book / eBook (14) 14
Newspaper Article (4) 4
Book Chapter (3) 3
Trade Publication Article (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (239) 239
humans (207) 207
oncology (202) 202
melanoma (169) 169
male (115) 115
female (112) 112
melanoma - drug therapy (111) 111
middle aged (98) 98
aged (89) 89
mutation (86) 86
cancer (85) 85
adult (84) 84
melanoma - genetics (79) 79
proto-oncogene proteins b-raf - genetics (73) 73
survival (71) 71
metastasis (70) 70
melanoma - pathology (68) 68
ipilimumab (63) 63
immunotherapy (62) 62
proto-oncogene proteins b-raf - antagonists & inhibitors (61) 61
metastatic melanoma (56) 56
vemurafenib (54) 54
cell biology (52) 52
metastases (52) 52
aged, 80 and over (50) 50
patients (50) 50
skin neoplasms - drug therapy (49) 49
care and treatment (48) 48
treatment outcome (46) 46
braf (42) 42
open-label (42) 42
skin neoplasms - pathology (39) 39
tumors (38) 38
clinical trials (37) 37
dabrafenib (37) 37
melanoma - mortality (37) 37
young adult (37) 37
article (36) 36
prognosis (36) 36
antineoplastic agents - therapeutic use (35) 35
mutations (35) 35
therapy (32) 32
analysis (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
protein kinase inhibitors - therapeutic use (31) 31
melanoma - secondary (30) 30
abridged index medicus (29) 29
disease-free survival (29) 29
nivolumab (29) 29
adolescent (28) 28
skin neoplasms - genetics (28) 28
hematology, oncology and palliative medicine (27) 27
imidazoles - administration & dosage (27) 27
mek inhibition (27) 27
oximes - administration & dosage (27) 27
acquired-resistance (26) 26
melanoma - metabolism (26) 26
risk factors (26) 26
drug therapy (25) 25
improved survival (25) 25
neoplasm metastasis (25) 25
biochemistry & molecular biology (23) 23
solid tumors (23) 23
antibodies, monoclonal - therapeutic use (22) 22
cell line, tumor (22) 22
kaplan-meier estimate (22) 22
medical research (22) 22
dermatology (21) 21
medicine, general & internal (21) 21
pathology (21) 21
pembrolizumab (21) 21
research (21) 21
skin neoplasms - mortality (21) 21
animals (20) 20
imidazoles - adverse effects (20) 20
immunohistochemistry (20) 20
mek inhibitors (20) 20
oximes - adverse effects (20) 20
resistance (20) 20
safety (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
chemotherapy (19) 19
disease progression (19) 19
expression (19) 19
imidazoles - therapeutic use (19) 19
immune checkpoint (19) 19
neoplasm staging (19) 19
oximes - therapeutic use (19) 19
patient outcomes (19) 19
proto-oncogene proteins b-raf - metabolism (19) 19
biomarkers (18) 18
diagnosis (18) 18
multicenter (18) 18
pd-1 protein (18) 18
studies (18) 18
cutaneous melanoma (17) 17
melanoma - therapy (17) 17
pyridones - administration & dosage (17) 17
pyrimidinones - administration & dosage (17) 17
toxicity (17) 17
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (6) 6
UTL at Downsview - May be requested (4) 4
Royal Ontario Museum - Stacks (3) 3
UofT at Mississauga - Stacks (2) 2
UofT at Scarborough - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Music - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Royal Ontario Museum - Reference (1) 1
St. Michael's College (John M. Kelly) - Reference (1) 1
Victoria University E.J. Pratt - Reference (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE MEDICINE, ISSN 1078-8956, 03/2019, Volume 25, Issue 3, pp. 356 - 356
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first... 
MEDICINE, RESEARCH & EXPERIMENTAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL BIOLOGY | Medical Oncology | Humans | Melanoma | Skin Neoplasms | Career Choice | Research | Australia | Health aspects | Epidemiology | Analysis | Public health | Medical research | Index Medicus
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 07/2019, Volume 10, Issue 1, pp. 1 - 15
Knowledge of key drivers and therapeutic targets in mucosal melanoma is limited due to the paucity of comprehensive mutation data on this rare tumor type. To... 
MUTATIONAL PROCESSES | PROFILE | MULTIDISCIPLINARY SCIENCES | BRAF FUSIONS | SENSITIVITY | NF1 | CANCER | SUBSET | CHEMOTHERAPY | MDM2 protein | Wnt protein | Therapeutic applications | p53 Protein | Mucosa | MEK inhibitors | Melanoma | Anorectal | Genomes | Cyclin-dependent kinase 4 | Gene sequencing | Landscapes | Point mutation | Histocompatibility antigen HLA | Mutation | Tumors
Journal Article
Cancer Research, ISSN 0008-5472, 07/2015, Volume 75, Issue 14 Supplement, pp. IA30 - IA30
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2018, Volume 119, Issue 6, pp. 661 - 662
A recent trial of adoptive cell therapy for the treatment of patients who progressed on checkpoint inhibitors indicates that resistance is not a consequence of... 
SURVIVAL | METASTATIC MELANOMA | ONCOLOGY | IMMUNOTHERAPY | IPILIMUMAB | Lymphocytes | Tumors | Tumour immunology | Melanoma
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2019, Volume 25, Issue 8, pp. 1319 - 1319
An amendment to this paper has been published and can be accessed via a link at the top of the paper. 
PD-1 protein | Immunotherapy | Melanoma | Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 09/2017, Volume 18, Issue 9, pp. e509 - e509
Journal Article
The Lancet. Oncology, ISSN 1470-2045, 09/2017, Volume 18, Issue 9, p. e509
Journal Article
Lancet Oncology, ISSN 1470-2045, 09/2017, Volume 18, Issue 9, p. e509
Journal Article
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2019, Volume 20, Issue 8, pp. 1083 - 1097
Immunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed... 
IMMUNE | ONCOLOGY | IDO | POOR-PROGNOSIS | INDOLEAMINE 2,3-DIOXYGENASE | NIVOLUMAB | EXPRESSION | IPILIMUMAB | Clinical trials | Care and treatment | Metastasis | Analysis | Melanoma | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2019, Volume 37, Issue 12, pp. 1031 - 1032
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.